Puma Biotechnology Inc - Common Stock — Flux de trésorerie trimestriel (NASDAQ:PBYI) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Total de l'actif 213.33 M196.18 M194.92 M202.86 M216.3 M192.7 M Total du passif 121.21 M99.07 M90.2 M87.59 M85.96 M64.28 M Total des capitaux propres 92.13 M97.11 M104.72 M115.27 M130.34 M128.42 M Total du passif et des capitaux propres 213.33 M196.18 M194.92 M202.86 M216.3 M192.7 M Dette totale 21.72 M10.65 M44.87 M33.72 M22.52 M11.28 M Dette nette -65.12 M-71.47 M-77.87 M-88.42 M-91.63 M-80.38 M

Puma Biotechnology Inc - Common Stock

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Nouvelles

PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript

Puma Biotechnology, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-05-08

Alerte résultats : Puma Biotech rate les prévisions au T1 2026

Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?

Puma Biotechnology T4 2025 : chiffre d’affaires NERLYNX en hausse de 15%

Puma Biotechnology présente de solides résultats pour le T4 2025

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?